Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC

[1]  Anala Gossai,et al.  Validation analysis of a composite real‐world mortality endpoint for patients with cancer in the United States , 2021, Health services research.

[2]  H. Rugo,et al.  Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer , 2021, The oncologist.

[3]  Jay J H Park,et al.  Synthetic and External Controls in Clinical Trials – A Primer for Researchers , 2020, Clinical epidemiology.

[4]  P. Xing,et al.  Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer , 2020, Frontiers in Oncology.

[5]  S. Baxi,et al.  Comparison of Population Characteristics in Real-World Clinical Oncology Databases in the US: Flatiron Health, SEER, and NPCR , 2020 .

[6]  S. Novello,et al.  Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Blay,et al.  Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Toh,et al.  Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions , 2020, Pharmacoepidemiology and drug safety.

[9]  N. Hanna,et al.  Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Joshua Haimson,et al.  Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research , 2020, ArXiv.

[11]  Jessica M Franklin,et al.  Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.

[12]  A. Drilon,et al.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  J. Mosser,et al.  Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study. , 2019, European journal of cancer.

[14]  A. Iafrate,et al.  Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer , 2018, Clinical Cancer Research.

[15]  M. Mishaeli,et al.  BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check‐Point Inhibitors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  Stephen R Cole,et al.  Transportability of Trial Results Using Inverse Odds of Sampling Weights. , 2017, American journal of epidemiology.

[17]  K. Goldberg,et al.  FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond , 2017, The oncologist.

[18]  D. Jayne,et al.  SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[19]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[20]  Bastien Cabarrou,et al.  Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[22]  Kari Lock Morgan,et al.  Balancing Covariates via Propensity Score Weighting , 2014, 1609.07494.

[23]  Jeanne Shen,et al.  Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[24]  Scott M Lippman,et al.  Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[25]  Antonio Marchetti,et al.  Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. , 2016, The Lancet. Oncology.

[28]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[29]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[30]  Handra,et al.  COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON–SMALL-CELL LUNG CANCER , 2001 .